Brucine Effect Metabolism Of Osteoblast And Osteoclast In Bone Disease Of Multiple Myeloma

Objective:To investigate pathway in early differentiation of osteoblasts and metabolism of osteoclasts in bone disease of multiple myeloma and the impact of in vitro brucine,as well as compare the influence between brucine and bortezomib in vitro bone disease of multiple myeloma.Methods:With MTT method, this paper may measured bortezomib and strychnine for multiple myeloma cell lines the IC50 concentration of U266. The author would add U266 multiple myeloma cell line supernatant to MC3T3-E1 osteoblast differentiation induction system. After culturing bacteria, RT-PCR method would be evaluated the mRNA level of alkaline phosphatase (ALP), osteocalcin (OC), osteoprotegerin (OPG) and osteoprotegerin ligand (RANKL).Results:the median inhibitory concentration (IC50)of Bortezomib for multiple myeloma cell lines U266 48 h was 22.4nmol/L and strychnine was 0.16 mg/ml. And levels of mRNA of strychnine and multiple myeloma cell supernatant common in the intervention group liquid osteoblast alkaline phosphatase (ALP), BGP (OC) and osteoprotegerin (OPG)were above the multiple myeloma cells into the supernatant in the intervention group bone cells (P<0.05), while the mRNA level of RANKL was reduced (P<0.05), and the higher or lower degree were beyond bortezomib group (P<0.05).Conclusion:the influence of brucine on bone disease in multiple myeloma bone metabolism were possibly through the regulation from osteoblasts to osteoclasts. The treatment effect of in vitro brucine was better than bortezomib for multiple myeloma and bone disease.